A research letter published on March 28 in the Journal of the American Medical Association (JAMA) found that the combined industries made more than 85 million payments to more than 820,300 (57 percent of) eligible physicians across 39 specialties from 2013 to 2022. Nearly 94 percent of the payments were related to one or more marketed medical products. Yeah, I'm gonna go with kickbacks. //

According to the JAMA report, the three drugs associated with the majority of payments were Xarelto ($176.34 million), Eliquis ($102.62 million), and Humira ($100.17 million).

The three medical devices associated with the majority of payments were the da Vinci Surgical System ($307.52 million), Mako SmartRobotics ($50.13 million), and CoreValve Evolut ($44.79 million).